Alzamend Neuro Gets FDA Approval for Trial of Depression Treatment
By Dean Seal
Alzamend Neuro has gotten the go-ahead from federal regulators to launch a clinical study of its treatment for major depressive disorder.
The biopharmaceutical company said Monday that it received a "Study May Proceed" letter from the U.S. Food and Drug Administration for a Phase IIA clinical study of AL001.
"We are grateful to receive this timely, favorable response from the FDA," Chief Executive Stephan Jackman said. "Although lithium does not have an FDA approved indication for augmentation of an antidepressant in MDD, it has been prescribed off-label for this purpose for decades."
Alzamend Neuro expects that the first patient will be dosed in the first quarter of 2024.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 20, 2023 08:32 ET (13:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom